Novartis (NOVN.SW) stock price, revenue, and financials

Novartis market cap is CHF179.9 b, and annual revenue was $47.45 b in FY 2019

CHF179.9 B

NOVN.SW Mkt cap, 19-Nov-2020

$12.3 B

Novartis Revenue Q3, 2020
Novartis Gross profit (Q3, 2020)8.5 B
Novartis Gross profit margin (Q3, 2020), %69.4%
Novartis Net income (Q3, 2020)1.9 B
Novartis EBIT (Q3, 2020)2.4 B
Novartis Cash, 30-Sept-20209 B
Novartis EV209.1 B

Novartis Revenue

Novartis revenue was $47.45 b in FY, 2019 which is a 8.6% year over year decrease from the previous period.

Embed Graph

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other

Novartis Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

49.1b51.9b47.4b

Revenue growth, %

1%6%(9%)

Cost of goods sold

16.1b17.1b13.2b

Gross profit

33.0b34.8b34.2b

Gross profit Margin, %

67%67%72%

Sales and marketing expense

12.9b

R&D expense

9.0b9.1b9.4b

General and administrative expense

2.1b16.5b14.4b

Operating expense total

24.3b26.6b25.2b

EBIT

8.6b8.2b9.1b

EBIT margin, %

18%16%19%

Interest expense

777.0m957.0m850.0m

Pre tax profit

9.0b13.8b8.9b

Income tax expense

1.3b1.2b1.8b

Net Income

7.7b12.6b11.7b

EPS

3.35.45.1

Novartis Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

8.9b13.3b11.1b

Accounts Receivable

8.6b8.7b8.3b

Inventories

6.9b7.0b6.0b

Current Assets

28.2b35.6b29.5b

PP&E

16.5b15.7b12.1b

Goodwill

31.8b35.3b26.5b

Total Assets

133.1b145.6b118.4b

Accounts Payable

5.2b5.6b5.4b

Short-term debt

5.3b9.7b7.3b

Current Liabilities

23.4b29.6b28.3b

Long-term debt

23.2b22.5b22.1b

Non-Current Liabilities

35.4b37.3b34.6b

Total Debt

28.5b32.1b29.3b

Total Liabilities

58.9b66.9b62.8b

Common Stock

969.0m944.0m936.0m

Total Equity

74.2b78.7b55.6b

Debt to Equity Ratio

0.4 x0.4 x0.5 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x

Financial Leverage

1.8 x1.8 x2.1 x

Novartis Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

7.7b12.6b7.1b

Depreciation and Amortization

6.9b5.8b

Accounts Receivable

(569.0m)(980.0m)

Inventories

(533.0m)(382.0m)

Accounts Payable

309.0m553.0m

Cash From Operating Activities

12.6b14.3b13.6b

Purchases of PP&E

(1.7b)(1.8b)(1.4b)

Cash From Investing Activities

(3.1b)(5.6b)(2.2b)

Short-term Borrowings

(755.0m)1.7b(1.6b)

Long-term Borrowings

(188.0m)(366.0m)(3.5b)

Dividends Paid

(6.5b)(7.0b)(6.6b)

Cash From Financing Activities

(7.7b)(4.2b)(13.6b)

Net Change in Cash

1.9b4.4b(2.2b)

Interest Paid

708.0m826.0m793.0m

Novartis Ratios

USDFY, 2017

EV/EBIT

22.6 x

EV/CFO

15.5 x

Revenue/Employee

403.9k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x

P/E Ratio

22.2

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Clinical Data Readouts

30

Major Approvals (US, EU, JP)

20 16 16 15

Major Submissions (US, EU, JP)

14 24 16 20 30

Patients Reached

972 m965 m927 m

Phase I/II Trials Products

114

Phase I/II Trials Products (Oncology)

57

Phase I/II Trials Products (Pharmaceuticals)

57

Phase III Trials Products

37 29 37 38

Phase III Trials Products (Biosimilars)

1

Phase III Trials Products (Oncology)

20

Phase III Trials Products (Pharmaceuticals)

17

Projects Entering Development Pipeline

8 5 9

Registration Phase Products

13

Registration Phase Products (Oncology)

3

Registration Phase Products (Pharmaceuticals)

10

US FDA Breakthrough Therapy Designations

5 6

Novartis Sustainability Metrics

 FY, 2019

Water Used (Cooling)

55.50 m cubic meters

Water Used (Contact)

11.20 m cubic meters

Water Used

66.70 m cubic meters

Water Recycled

14.70 m cubic meters

Water Purchased (Suppliers)

9.30 m cubic meters

Water Lost

1.20 m cubic meters

Water Emissions (Total Suspended Solids)

198.20 tonnes

Water Emissions (Phosphate)

34.70 tonnes

Water Emissions (Nitrogen)

207.50 tonnes

Water Emissions (Chemical Oxygen Demand)

1.84 k tonnes

Water Discharged

9.90 m cubic meters

Total Recordable Incident Rate

0.36

Purchased Energy Used (Total)

6.68 m GJ

On-Site Generated Energy Used (Total)

6.19 m GJ

Nonhazardous Waste Recycled, percent

81.7%

Nonhazardous Waste (Recycled)

57.70 k tonnes

Nonhazardous Waste (Landfilled)

4.10 k tonnes

Nonhazardous Waste (Incinerated)

8.40 k tonnes

Nonhazardous Waste (Bio/Chemical Treatment)

400 tonnes

Lost Time Illness Rate

0.18

Hazardous Waste Recycled, percent

58.8%

Hazardous Waste (Recycled)

58.80 k tonnes

Hazardous Waste (Incinerated)

37.20 k tonnes

Hazardous Waste (Bio/Chemical Treatment)

4 k tonnes

Greenhouse Gas Emissions (Scope 3, Business Travel)

191.30 k tonnes

Greenhouse Gas Emissions (Scope 2, Market-Based)

411.60 k tonnes

Greenhouse Gas Emissions (Scope 2, Location-Based)

564.50 k tonnes

Greenhouse Gas Emissions (Scope 1, Fuel Combustion)

356.20 k tonnes

Greenhouse Gas Emissions (Scope 1, Fleet Vehicles)

128.40 k tonnes

Greenhouse Gas Emissions (Scope 1 and Scope 2) Intensity

18.90 metric tons of carbon dioxide equivalent per mio USD

Greenhouse Gas Emissions (Scope 1 and Scope 2)

896.10 k tonnes

Environmental Fines or Penalties Paid

$11.30 k

Energy Used from Renewable Energy Sources

2.25 m GJ

Energy Used

12.75 m GJ

Energy Use Intensity per employee

137.20 GJ/employee

Energy Use Intensity

314.80 GJ/100 square meters

Energy Sold

130 k GJ

Air Emissions (Sulfur Oxide)

4.56 tonnes

Air Emissions (Particulate Matter)

12.91 tonnes

Air Emissions (Non-Halogenated Volatile Organic Compounds)

406.82 tonnes

Air Emissions (Nitrogen Oxides)

236.32 tonnes

Air Emissions (Halogenated Volatile Organic Compounds)

26.59 tonnes

Novartis Human Capital

Job Roles

FY, 2019FY, 2018FY, 2017
Male (Board), percent25 %25 %25.7 %
Female (Leadership), percent10.3 %9.3 %9 %
Male (Leadership), percent23 %24 %24.3 %
Female (Senior Management), percent12.7 %12 %11.3 %
Male (Senior Management), percent20.7 %21.3 %22 %
Female (Board), percent8.3 %8.3 %7.7 %
FY, 2019FY, 2018FY, 2017
Female, percent22 %21 %20.5 %
Male, percent28 %29 %29.5 %
Male (Middle Management), percent27.5 %28.5 %29 %
Female (Middle Management), percent22.5 %21.5 %21 %

Novartis Employee Rating

4.14372 votes
Culture & Values
4
Work/Life Balance
3.9
Senior Management
3.5
Salary & Benefits
4
Career Opportunities
3.7
Source